Article

The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies.

School of Psychology, Laval University, Quebec City, QC, Canada.
Journal of Neuropsychiatry (Impact Factor: 2.77). 02/2004; 16(4):409-25. DOI: 10.1176/appi.neuropsych.16.4.409
Source: PubMed

ABSTRACT Dementia with Lewy bodies (DLB) is a common cause of dementia with effects on cognition, mood, behavior, and function. Changes in the acetylcholine system have been reported in brains of patients with DLB, which provides a rationale for trials of acetylcholinesterase inhibitors in DLB. This review includes all English-language publications found via Medline and related to the efficacy and/or safety of these compounds in DLB. Preliminary data suggest that these compounds may be efficacious in DLB and that future randomized clinical trials are strongly needed. Methodological limitations of the existing data include small sample sizes, and the paucity of standardized psychometric measures.

0 Followers
 · 
96 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and Purpose The substantia innominata (SI) contains the nucleus basalis of Meynert, which is the major source of cholinergic input to the cerebral cortex. We hypothesized that degeneration of the SI and its relationship to general cognitive performance differs in amyloidopathy and synucleinopathy. Methods We used magnetic resonance imaging (MRI)-based volumetric analysis to evaluate the SI volume in patients with amnestic mild cognitive impairment (aMCI), Alzheimer’s disease (AD), Parkinson’s disease-mild cognitive impairment (PD-MCI), PD with dementia (PDD), dementia with Lewy bodies (DLB), and healthy elderly controls. The correlation between SI volume and general cognitive performance, measured using the Korean version of the Mini-Mental State Examination (K-MMSE), was examined. Results Compared to control subjects, the mean normalized SI volume was significantly decreased in all of the other groups. The normalized SI volume did not differ between the subjects with PDD and DLB, whereas it was significantly smaller in subjects with PDD (p = 0.029) and DLB (p = 0.011) compared with AD. In subjects with PD-related cognitive impairment (PD-MCI, PDD, or DLB), there was a significant positive correlation between the SI volume and K-MMSE score (r = 0.366, p < 0.001), whereas no correlation was seen in subjects with AD-related cognitive impairment (aMCI or AD). Conclusions Our data suggest that the SI loss is greater in synucleinopathy-related dementia (PDD or DLB) than in AD and that the contribution of the SI to cognitive performance is greater in synucleinopathy than in amyloidopathy.
    10/2011; 4(2):68-72. DOI:10.14802/jmd.11014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Demenz mit Lewy-Körperchen (Demenz mit Lewy bodies, DLB) stellt die zweihäufigste degenerative Demenzform jenseits des 65. Lebensjahres dar. Klinisch ist die Erkrankung durch ein demenzielles Syndrom, spontane extrapyramidale motorische Symptome (EPMS), Halluzinationen und Fluktuationen der Aufmerksamkeit charakterisiert. Die postulierten klinischen Diagnosekriterien sind vor allem bei der Abgrenzung zu einer Alzheimer-Demenz sehr hilfreich. Bei der DLB liegt ein ausgeprägtes cholinerges Defizit vor, das für eine vielgestaltige Symptomatik mit Demenz und psychotischen Symptomen verantwortlich ist. Wir berichten über einen 83-jährigen, an einer DLB erkrankten Patienten, der sich aufgrund von fluktuierenden Verwirrtheitszuständen und optischen Halluzinationen vorstellte. Nachdem mehrere atypische Neuroleptika keinen Effekt zeigten, erbrachte eine Behandlung mit einem Acetylcholinesteraseinhibitor (Donepezil) eine deutliche Besserung der Kognition und der Verhaltensauffälligkeiten.
    Der Nervenarzt 01/2007; 78(9). · 0.86 Impact Factor
  • Source
    10/2007; 36:157-174.

Full-text (2 Sources)

Download
72 Downloads
Available from
Jun 4, 2014